Literature DB >> 30723936

Augmented Renal Clearance.

Aaron M Cook1,2, Jimmi Hatton-Kolpek2.   

Abstract

Augmented renal clearance (ARC) is a phenomenon in critically ill patients characterized by increased creatinine clearance and elimination of renally eliminated medications. Patients with severe neurologic injury, sepsis, trauma, and burns have been consistently identified as at risk of ARC, with mean creatinine clearances ranging from 170 ml/minute to more than 300 ml/minute. Several potential mechanisms may contribute to the occurrence of ARC including endogenous responses to increased metabolism and solute production, alterations in neurohormonal balance, and therapeutic maneuvers such as fluid resuscitation. Augmented renal clearance is associated with suboptimal exposure to critical medications, including β-lactams and vancomycin, increasing the risk of treatment failure. Although definitive screening tools are not yet known, critical care pharmacists must be vigilant in recognizing when ARC may be a contributing factor affecting expected treatment outcomes in individual patients. Optimizing dosing strategies in critically ill patients with ARC remains a goal of continued research. The current review discusses the clinical characteristics and methods of identifying patients at risk of ARC, potential mechanisms for ARC, and describes pharmacotherapy dosing considerations in patients with ARC.
© 2019 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  antiepileptic drugs; critical care; pharmacokinetics; septic shock; β-lactams

Mesh:

Substances:

Year:  2019        PMID: 30723936     DOI: 10.1002/phar.2231

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  30 in total

1.  Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.

Authors:  Sean N Avedissian; Roxane Rohani; John Bradley; Jennifer Le; Nathaniel J Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens.

Authors:  T Nguyen; M Oualha; C Briand; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; F Foissac; S Winter; I Gana; S Boujaafar; V Lopez; R Berthaud; Z Demir; N Bouazza; D Hirt
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Risk factors associated with augmented renal clearance in a mixed intensive care unit population: a retrospective study.

Authors:  Emily Bing; Kym Archambault; Alice Sananikone; Kim-Dan Nguyen; Yi Tong Fang; Caren Jabamikos; Cécile Gras; Amélie Marsot; Marc-Alexandre Duceppe; Marc M Perreault
Journal:  Int J Clin Pharm       Date:  2022-07-14

4.  Risk Factors Associated With Prolonged Antibiotic Use in Pediatric Bacterial Meningitis.

Authors:  Cuiyao He; Xiaogang Hu; Tingsong Li; Qing Wu; Jisan Fan; Yan Zhou; Li Jiang; Siqi Hong; Yuanyuan Luo
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

5.  Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens.

Authors:  S Abdalla; C Briand; M Oualha; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; C Capito; Z Demir; F Foissac; S Winter; I Gana; S Boujaafar; N Bouazza; D Hirt
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

6.  Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.

Authors:  Norma A Aréchiga-Alvarado; Susanna E Medellín-Garibay; Rosa Del C Milán-Segovia; Arturo Ortiz-Álvarez; Martín Magaña-Aquino; Silvia Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

7.  Pharmacists' Knowledge About the Impact of Augmented Renal Clearance on Antimicrobial Dosing in Critically Ill Patients: A Cross-Sectional Study.

Authors:  Abdulaziz S Almulhim; Batool A Al-Dahneen; Yazed S Alsowaida
Journal:  Infect Dis Ther       Date:  2020-06-27

8.  Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study.

Authors:  Pier Giorgio Cojutti; Davide Lazzarotto; Anna Candoni; Maria Vittoria Dubbini; Maria Elena Zannier; Renato Fanin; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

9.  Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.

Authors:  D Hirt; M Oualha; B Pasquiers; S Blanot; R Rubinstazjn; C Glorion; S El Messaoudi; D Drummond; V Lopez; J Toubiana; A Béranger; Sana Boujaafar; Yi Zheng; Carmen Capito; S Winter; P L Léger; R Berthaud; Inès Gana; F Foissac; J M Tréluyer; N Bouazza; S Benaboud
Journal:  Eur J Clin Pharmacol       Date:  2021-06-23       Impact factor: 2.953

10.  Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs.

Authors:  Yifei Zhang; Catherine M Sherwin; Daniel Gonzalez; Qunshu Zhang; Mona Khurana; Jeffrey Fisher; Gilbert J Burckart; Yaning Wang; Lynne P Yao; Charles J Ganley; Jian Wang
Journal:  Clin Pharmacol Ther       Date:  2020-08-29       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.